LexDanaLexDanabeta
Inventor

Sanjay Bhanot

Inventor
Carlsbad, CA, US

Overview

59→
Patents
2007–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 59 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes20%
C12YEnzymes10%
C07HSugars7%
Y02PClimate change mitigation technologies in the production or processing of goods3%
C07KPeptides2%
A01KAnimal husbandry1%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms0%
PatentTitleYear
10,858,657Methods for treating hypercholesterolemia202010,793,862Compositions and methods for modulating growth hormone receptor expression2020RE048060Antisense modulation of PTP1B expression20209,994,842Methods for use in modulating miR-122A20189,994,855Compositions and methods for modulating growth hormone receptor expression20189,650,636'Methods for treating hypercholesterolemia'20179,617,540'Compounds and methods for modulating gene expression'20179,567,587'Antisense modulation of GCCR expression'20179,404,114'Antisense modulation of GCGR expression'20169,404,113'Antisense modulation of PTP1B expression'20169,045,754'Short antisense compounds with gapmer configuration'20159,034,842'Antisense modulation of PTP1B expression'20158,969,314'Methods for use in modulating miR-122a'20158,969,316'Compounds and methods for modulating expression of DGAT2'20158,933,213'Antisense modulation of fibroblast growth factor receptor 4 expression'20158,912,160'Methods for treating hypercholesterolemia'20148,901,098'Antisense modulation of GCCR expression'20148,895,529'Antisense modulation of fibroblast growth factor receptor 4 expression'20148,883,997'Modulation of diacylglycerol acyltransferase 2 expression'20148,865,674'Antisense modulation of GCGR expression'20148,853,178'Antisense modulation of PTP1B expression'20148,778,900'Modulation of eIF4E-BP1 expression'20148,673,871'Compounds and methods for modulating expression ApoB'20148,664,190'Methods for treating hypercholesterolemia'20148,658,783'Antisense modulation of PTP1B expression'20148,642,753'Modulation of glucagon receptor expression'20148,586,554'Compounds and methods for modulating expression of PTP1B'20138,580,948'Modulation of forkhead box O1A expression'20138,541,388'Methods for modulating expression of RBP4'20138,541,387'Modulation of SMRT expression'20138,486,904'Antisense modulation of fibroblast growth factor receptor 4 expression'20138,455,456'Compositions and their uses directed to diacylglycerol acyltransferase 1'20138,372,967'Compounds and methods for modulating expression of GCCR'20138,362,232'Compounds and methods for modulating expression of SGLT2'20138,299,041'Compositions and their uses directed to acetyl-CoA carboxylases'20128,258,289'Modulation of diacylglycerol acyltransferase 2 expression'20128,258,114'Modulation of glucose-6-phosphatase translocase expression'20128,227,593'Modulation of forkhead box O1A expression'20128,202,981'Compositions and their uses directed to PTPRU'20128,188,059'Compounds and methods for modulating expression of GCGR'20128,158,598'Compositions and their uses directed to PTPR alpha'20128,143,230'Compounds and methods for modulating expression of PCSK9'20128,101,585'Compositions and methods for the modulation of JNK proteins'20128,093,222'Methods for treating hypercholesterolemia'20128,084,437'Methods for treating hypercholesterolemia'20118,067,386'Modulation of eIF4E-BP2 expression'20118,017,760'Antisense modulation of PTP1B expression'20118,003,620'Compositions and their uses directed to diacylglycerol acyltransferase 1'20117,960,358'Antisense modulation of stearoyl-CoA desaturase expression'20117,919,476'Modulation of glucagon receptor expression'20117,919,472'Enhanced antisense oligonucleotides'20117,897,583'Compositions and their uses directed to PTPRU'20117,825,235'Modulation of diacylglycerol acyltransferase 2 expression'20107,807,649'Modulation of forkhead box O1A expression'20107,807,652'Modulation of eIF4E-BP2 expression'20107,732,590'Modulation of diacylglycerol acyltransferase 2 expression'20107,468,431'Modulation of eIF4E-BP2 expression'20087,399,853'Modulation of glucagon receptor expression'20087,229,976'Modulation of forkhead box O1A expression'2007

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2007–2017Patents assigned to ISIS PHARMACEUTICALS INC (49)· patent assignee history
2007Based in Encinitas, CA, US· patent location history
2008–2020Based in Carlsbad, CA, US· patent location history
2011–2015Patents assigned to BHANOT SANJAY (29)· patent assignee history
2011–2014Patents assigned to DOBIE KENNETH W (10)· patent assignee history
2012–2015Patents assigned to MONIA BRETT P (14)· patent assignee history
2012–2015Patents assigned to MCKAY ROBERT (13)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ISIS PHARMACEUTICALS INC492007–2017
BHANOT SANJAYself292011–2015
MONIA BRETT P142012–2015
MCKAY ROBERT132012–2015
DOBIE KENNETH W102011–2014
Locations
LocationPatentsSpan
Carlsbad, California, US582008–2020
Encinitas, California, US12007